CAPTRUST Financial Advisors
RPRX icon

CAPTRUST Financial Advisors’s Royalty Pharma RPRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
337,298
+193,538
+135% +$10.1M 0.03% 408
2026
Q1 		$6.9M Buy
143,760
+129,816
+931% +$5.69M 0.01% 640
2025
Q4 		$539K Buy
13,944
+2,129
+18% +$81.2K ﹤0.01% 1860
2025
Q3 		$417K Sell
11,815
-798
-6% -$28.9K ﹤0.01% 1948
2025
Q2 		$454K Buy
12,613
+526
+4% +$17.4K ﹤0.01% 1790
2025
Q1 		$376K Sell
12,087
-2,742
-18% -$86.9K ﹤0.01% 1813
2024
Q4 		$378K Sell
14,829
-14,499
-49% -$384K ﹤0.01% 1769
2024
Q3 		$830K Sell
29,328
-1,596
-5% -$44.2K ﹤0.01% 1296
2024
Q2 		$815K Sell
30,924
-2,535
-8% -$70.3K ﹤0.01% 1250
2024
Q1 		$1.02M Sell
33,459
-5,589
-14% -$165K ﹤0.01% 1118
2023
Q4 		$1.1M Sell
39,048
-17,872
-31% -$491K ﹤0.01% 1192
2023
Q3 		$1.54M Sell
56,920
-4,745
-8% -$141K 0.01% 968
2023
Q2 		$1.9M Buy
61,665
+26
+0% +$881 0.01% 853
2023
Q1 		$2.22M Sell
61,639
-3,999
-6% -$148K 0.01% 710
2022
Q4 		$2.59M Buy
65,638
+1,484
+2% +$61.9K 0.01% 630
2022
Q3 		$2.58M Buy
64,154
+63,866
+22,176% +$2.73M 0.02% 588
2022
Q2 		$12K Buy
288
+29
+11% +$1.19K ﹤0.01% 3662
2022
Q1 		$10K Buy
259
+112
+76% +$4.4K ﹤0.01% 3814
2021
Q4 		$6K Sell
147
-60
-29% -$2.33K ﹤0.01% 4000
2021
Q3 		$7K Buy
207
+200
+2,857% +$7.77K ﹤0.01% 3818
2021
Q2 		$0 Buy
+7
New +$298 ﹤0.01% 4634

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAPTRUST Financial Advisors's RPRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Royalty Pharma (RPRX) stake by 135% in Q2 2026, buying an estimated $10.1M and bringing the position to 337,298 shares worth $18.9M. The position accounts for 0.03% of the portfolio, ranked #408.

CAPTRUST Financial Advisors first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • CAPTRUST Financial Advisors held 337,298 shares of Royalty Pharma worth $18.9M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 193,538 Royalty Pharma shares in Q2 2026, an estimated $10.1M.
  • Royalty Pharma made up 0.03% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #408 holding.
  • CAPTRUST Financial Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.